Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
Clinical trial NCT03970837 · TERMINATED
Trial details
- NCT number
- NCT03970837
- Sponsor
- GlaxoSmithKline
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-05
- Primary completion
- 2021-10-29
- Enrollment
- 1764
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.